Manufacturer of Controlled Substances; Notice of Registration; Chemtos, LLC, 75671-75672 [2012-30781]

Download as PDF 75671 Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of AMRI Rensselaer, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated AMRI Rensselaer, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: December 18, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration mstockstill on DSK4VPTVN1PROD with Manufacturer of Controlled Substances; Notice of Registration; Rhodes Technologies Jkt 229001 [FR Doc. 2012–30785 Filed 12–20–12; 8:45 am] BILLING CODE 4410–09–P Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: December 14, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–30783 Filed 12–20–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Registration; Euticals, Inc. Drug Enforcement Administration Drug Manufacturer of Controlled Substances; Notice of Registration; Chemtos, LLC By Notice dated July 30, 2012, and published in the Federal Register on August 7, 2012, 77 FR 47116, Chemtos, LLC, 14101 W. Highway 290, Building 2000B, Austin, Texas 78737–9331, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Schedule Drug By Notice dated May 31, 2012, and published in the Federal Register on June 8, 2012, 77 FR 34072, Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of morphine (9300), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance in bulk for conversion and sale to dosage form manufacturers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Rhodes Technologies to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Rhodes Technologies to ensure that the company’s registration is consistent with the public interest. The 18:28 Dec 20, 2012 Dated: December 14, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. By Notice dated August 17, 2012, and published in the Federal Register on August 29, 2012, 77 FR 52367, Euticals, Inc., (formerly known as Archimica, Inc.), 2460 W. Bennett Street, Springfield, Missouri 65807–1229, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: [FR Doc. 2012–30780 Filed 12–20–12; 8:45 am] VerDate Mar<15>2010 investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Gamma Hydroxybutyric Acid (2010). Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Phenylacetone (8501) .................. Methadone Intermediate (9254) ... Tapentadol (9780) ........................ II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers. With regards to amphetamine (1100), the company plans to acquire the listed controlled substance in bulk from a domestic source in order to manufacture other controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Euticals, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Euticals, PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 Schedule I Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Nabilone (7379) ............................ Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Etorphine HCL (9059) .................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Levomethorphan (9210) ............... Levorphanol (9220) ...................... Isomethadone (9226) ................... Meperidine (9230) ........................ Meperidine-intermediate-A (9232) Meperidine-intermediate-B (9233) Meperidine-intermediate-C (9234) Methadone (9250) ........................ Methadone intermediate (9254) ... Morphine (9300) ........................... Thebaine (9333) ........................... Dihydroetorphine (9334) ............... Levo-alphacetylmethadol (9648) .. E:\FR\FM\21DEN1.SGM 21DEN1 II II II II II II II II II II II II II II II II II II II II II II II II II II II II 75672 Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices Drug Schedule Oxymorphone (9652) ................... Racemethorphan (9732) .............. Racemorphan (9733) ................... II II II The company plans to manufacture small quantities of the listed controlled substances in bulk for distribution to its customers for use as reference standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Chemtos, LLC, to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Chemtos, LLC, to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. The company plans to manufacture Hydromorphone HCL for sale to other manufacturers, and for the manufacture of other controlled substance dosage units for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Halo Pharmaceutical, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Halo Pharmaceutical, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: December 14, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Dated: December 14, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–30774 Filed 12–20–12; 8:45 am] [FR Doc. 2012–30781 Filed 12–20–12; 8:45 am] NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES BILLING CODE 4410–09–P FOR FURTHER INFORMATION CONTACT: BILLING CODE 4410–09–P Arts Advisory Panel Meeting DEPARTMENT OF JUSTICE National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting. AGENCY: Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Registration, Halo Pharmaceutical, Inc. mstockstill on DSK4VPTVN1PROD with Schedule Dihydromorphine (9145) ............... Hydromorphone (9150) ................ I II Dihydromorphine is an intermediate in the manufacture of Hydromorphone and is not for commercial distribution. VerDate Mar<15>2010 18:28 Dec 20, 2012 Jkt 229001 Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), as amended, notice is hereby given that seven meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks Center, 1100 Pennsylvania Avenue NW., Washington, DC 20506 (unless otherwise noted) as follows (ending times are approximate): International (application review): By teleoconference. This meeting will be closed. Dates: January 8, 2013; 1:00 p.m. to 2:00 p.m. e.s.t. Folk & Traditional Arts (application review): In room 716. This meeting will be closed. Dates: January 11, 2013; 9:00 a.m. to 5:30 p.m. e.s.t. SUMMARY: By Notice dated July 30, 2012, and published in the Federal Register on August 7, 2012, 77 FR 47114, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany, New Jersey 07981, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug State & Regional (review of state partnership agreements): In Room 716. This meeting will be open. Dates: January 16–17, 2013; From 9:00 a.m. to 5:00 p.m. e.s.t. on January 16th and from 9:00 a.m. to 3:30 p.m. e.s.t. on January 17th. Music (review of nominations): 3 Columbus Circle, 12th Floor, New York, NY 10019 and by teleconference. This meeting will be closed. Dates: January 15, 2013, from 9:00 a.m. to 10:15 a.m. e.s.t. State & Regional (review of regional partnership agreements): By teleconference. This meeting will be open. Dates: January 30, 2013; From 3:00 p.m. to 4:00 p.m. e.s.t. Folk & Traditional Arts (review of nominations): In room 716. This meeting will be closed. Dates: January 29–February 1, 2013; from 9:00 a.m. to 5:30 p.m. e.s.t. on January 29th–31st and from 9:00 a.m. to 1:00 p.m. e.s.t. on February 1st. Research (application review): In Room 627. This meeting will be closed. Dates: January 29–30, 2013; From 9:00 a.m. to 5:30 p.m. e.s.t. on January 29th and from 9:00 a.m. to 5:00 p.m. e.s.t. on January 30th. PO 00000 Frm 00067 Fmt 4703 Sfmt 9990 Further information with reference to these meetings can be obtained from Ms. Kathy Plowitz-Worden, Office of Guidelines & Panel Operations, National Endowment for the Arts, Washington, DC 20506; plowitzk@arts.gov or call 202/682–5691. The closed portions of meetings are for the purpose of Panel review, discussion, evaluation, and recommendations on financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including information given in confidence to the agency. In accordance with the determination of the Chairman of February 15, 2012, these sessions will be closed to the public pursuant to subsection (c)(6) of section 552b of Title 5, United States Code. SUPPLEMENTARY INFORMATION: Dated: December 18, 2012. Kathy Plowitz-Worden, Panel Coordinator, National Endowment for the Arts. [FR Doc. 2012–30759 Filed 12–20–12; 8:45 am] BILLING CODE 7537–01–P E:\FR\FM\21DEN1.SGM 21DEN1

Agencies

[Federal Register Volume 77, Number 246 (Friday, December 21, 2012)]
[Notices]
[Pages 75671-75672]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-30781]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Chemtos, LLC

    By Notice dated July 30, 2012, and published in the Federal 
Register on August 7, 2012, 77 FR 47116, Chemtos, LLC, 14101 W. Highway 
290, Building 2000B, Austin, Texas 78737-9331, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the following basic classes of controlled 
substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Nabilone (7379)............................  II
Phenylacetone (8501).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Etorphine HCL (9059).......................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Ecgonine (9180)............................  II
Ethylmorphine (9190).......................  II
Hydrocodone (9193).........................  II
Levomethorphan (9210)......................  II
Levorphanol (9220).........................  II
Isomethadone (9226)........................  II
Meperidine (9230)..........................  II
Meperidine-intermediate-A (9232)...........  II
Meperidine-intermediate-B (9233)...........  II
Meperidine-intermediate-C (9234)...........  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Dihydroetorphine (9334)....................  II
Levo-alphacetylmethadol (9648).............  II

[[Page 75672]]

 
Oxymorphone (9652).........................  II
Racemethorphan (9732)......................  II
Racemorphan (9733).........................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances in bulk for distribution to its customers for use 
as reference standards.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a), and determined that the registration 
of Chemtos, LLC, to manufacture the listed basic classes of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated Chemtos, LLC, to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic classes of controlled substances listed.

    Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-30781 Filed 12-20-12; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.